Sulbactam

DRUG3 trials

Conditions

Acinetobacter Baumannii InfectionAcinetobacter Baumannii-calcoaceticus ComplexAcinetobacter InfectionsBacteremiaColistin Resistant ABCHospital-acquired Bacterial PneumoniaVentilator-associated Bacterial Pneumonia

Phase 1

Evaluation of the Safety, Tolerability and Pharmacokinetics of Intravenous ETX2514 Administered in Healthy Subjects

CompletedNCT02971423

Entasis TherapeuticsAcinetobacter Baumannii Infection

Start: 2016-10-31End: 2017-06-01Updated: 2017-06-05

Phase 3

Study to Evaluate the Efficacy and Safety of Intravenous Sulbactam-ETX2514 in the Treatment of Patients With Infections Caused by Acinetobacter Baumannii-calcoaceticus Complex

CompletedNCT03894046

Entasis TherapeuticsAcinetobacter Baumannii-calcoaceticus Complex, Bacteremia, Colistin Resistant ABC +2

Start: 2019-09-05End: 2021-07-26Updated: 2023-02-01

Phase 4

Pharmacodynamics Modeling to Optimize Dosage Regimens of Sulbactam in Patients With Acinetobacter Infections

CompletedNCT02688322

Sutep JaruratanasirikulAcinetobacter Infections

Start: 2014-09-30End: 2016-08-31Updated: 2017-09-20

Related Papers

Efficacy and safety of sulbactam-durlobactam versus colistin for the treatment of patients with serious infections caused by Acinetobacter baumannii-calcoaceticus complex: a multicentre, randomised, active-controlled, phase 3, non-inferiority clinical trial (ATTACK).

2023-05-11176 citations

Safety, Pharmacokinetics, and Drug-Drug Interaction Potential of Intravenous Durlobactam, a β-Lactamase Inhibitor, in Healthy Subjects.